Subcutaneous RYBREVANT® (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
WebMD

Treating Lung Cancer With Rybrevant: What You Should Know

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. If you have been diagnosed with NSCLC, your health care provider may test your cancer to see if it has certain genetic ...